Jamie O'Toole

2 months ago | medestheticsmag.com | Jamie O'Toole

Dermalogica launched its Exo Booster, a bacterial, pro-resolution technology combined with a vegan exosome complex containing approximately 10 billion Lactobacillus exosomes in each application, according to a Jan. 10 announcement. Log in to view the full articleDermalogica launched its Exo Booster, a bacterial, pro-resolution technology combined with a vegan exosome complex containing approximately 10 billion Lactobacillus exosomes in each application, according to a Jan. 10 announcement.

Jan 23, 2025 | medestheticsmag.com | Jamie O'Toole

New Data from Qsight Market View reveals that U.S. patients spent $3.08 billion on energy-based devices (EBD) procedures in 2023—nearly matching dermal fillers’ $3.18 billion. EBD procedures are set to close the spending gap with dermal fillers, solidifying their position as a preferred choice for achieving natural-looking cosmetic results.

Jan 21, 2025 | medestheticsmag.com | Jamie O'Toole

Recent data from Guidepoint Qsight reveals that GLP-1 medications for weight loss has reshaped the aesthetics market, with revenue at practices offering GLP-1 treatments increasing by an average of 9%, compared to a 2% decline at practices that did not offer these drugs.

Jan 17, 2025 | medestheticsmag.com | Jamie O'Toole

Going into 2025, Allergen Aesthetics foresees an uptick in aesthetics demand resulting from the rapid fat loss caused by GLP-1 use–specifically treatments that retain a natural look. Innovation in minimally invasive treatments that address “after” concerns, including skin care and muscle building therapies, will not only enhance the initial goal, weight loss, but also enable the next: undetectable, minimally invasive outcomes that align with their natural self.

Jan 16, 2025 | medestheticsmag.com | Jamie O'Toole

Amidst projected surges in the physician-dispensed skin care market, Carmell Cosmetics has acquired Elevai Labs, a manufacturer of physician-dispensed, exosome-based products to deepen Carmell’s advancement: secretomes. According to Straits Research, the physician dispensed market size was valued at $10.7 billion in 2023 and is estimated to reach $23.83 billion by 2032, growing at a CAGR of 8.3%.